Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/275
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mano, Antonio | - |
dc.contributor.author | Falcão, Amílcar | - |
dc.contributor.author | Godinho, I. | - |
dc.contributor.author | Santos, J. | - |
dc.contributor.author | Leitão, F. | - |
dc.contributor.author | Oliveira, C. | - |
dc.contributor.author | Caramona, M. | - |
dc.date.accessioned | 2008-06-17T15:01:57Z | - |
dc.date.available | 2008-06-17T15:01:57Z | - |
dc.date.issued | 2005-05 | - |
dc.identifier.citation | Gynecologic Oncology 97:2 (2005) 529-534 | en_US |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.uri | https://hdl.handle.net/10316/275 | - |
dc.description | Prémio atribuído pelo International Research Promotion Council a Amílcar C. Falcão: Eminent Scientist of the Year 2006. Europe | - |
dc.description.abstract | Abstract Objective The aim of the present study was to investigate the usefulness of the CA-125 area under the curve (AUC) as a new kinetic parameter for predicting overall survival in patients with ovarian cancer. In addition, the relationship of CA-125 AUC with other prognostic factors of ovarian cancer was evaluated. Methods Ninety-two patients that underwent primary line chemotherapy within 4 months after submission to cytoreductive surgery were included. For each patient, CA-125 AUC was calculated and a statistical analysis was conducted to compare CA-125 AUC behavior among patients according to several covariates. Results The mean age at diagnostic time was found to be 55.5 (16.1–82.4) years with a mean survival of 39.2 (3.5–100.1; SE = 2.6) months. Across FIGO stage I, II, III, and IV patients had a mean CA-125 AUC of 18.2, 24.6, 147.8, and 574.6 IU/ml*days, respectively (P < 0.05). At the evaluation date, living patients had a mean CA-125 AUC of 40.1 in contrast to 234.1 IU/ml*days (P < 0.05) for deceased ones. Patients with a complete response to primary chemotherapy had a mean CA-125 AUC of 48.8, while patients with a partial response had a mean of 251.7 IU/ml*days, and patients with no response or disease progression had a mean of 316.5 IU/ml*days (P < 0.05). The best CA-125 AUC performance is in predicting patient complete response to chemotherapy with a cut-off of 100 IU/ml*days and an accuracy of 82%. Conclusions Despite CA-125 AUC high correlation with the FIGO stage, residual disease, and patient final outcome, the main interest of CA-125 AUC calculation is to evaluate the treatment efficacy and to foresee a full chemotherapy response. Further studies should be carried out before extrapolating these results to other data sets. | en_US |
dc.format.mimetype | aplication/PDF | en |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | openAccess | eng |
dc.subject | neoplasias do ovario | en_US |
dc.subject | prognostico | en_US |
dc.subject | marcadores tumorais | en_US |
dc.subject | farmacocinética | en_US |
dc.subject | CA 125 | en_US |
dc.title | CA-125 AUC as a new prognostic factor for patients with ovarian cancer | en_US |
dc.type | article | en_US |
dc.identifier.doi | 10.1016/j.ygyno.2005.01.040 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
item.fulltext | Com Texto completo | - |
item.languageiso639-1 | en | - |
crisitem.author.researchunit | CEMMPRE - Centre for Mechanical Engineering, Materials and Processes | - |
crisitem.author.orcid | 0000-0002-3854-6549 | - |
crisitem.author.orcid | 0000-0003-4936-9434 | - |
crisitem.author.orcid | 0000-0003-1950-9360 | - |
Appears in Collections: | FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
CA-125.pdf | 239.33 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.